KFKazutaka Fukumura

Kazutaka Fukumura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazutaka Fukumura has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures1 from Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa Duose, Yujin Kudo, Banu Arun, et al.

  • Open Access

    Supplementary Table 1 from Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa Duose, Yujin Kudo, Banu Arun, et al.

  • Open Access

    Data from Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa Duose, Yujin Kudo, Banu Arun, et al.

    Purpose:Brain metastasis (BM) is a deadly complication of systemic malignancy that has been associated with defective cellular immunity. We sought to characterize the foundational elements and clinical relevance of BM-associated immunosuppression using integrated molecular profiling in primary patient material.Experimental Design:Retrospective patient tissue cohorts of breast (n = 153) and lung (n = 153) cancer BM were stratified by histopathologic scoring of tumor-infiltrating lymphocytes (TIL) and clinical outcome, with a large subset of breast cancer samples further analyzed by T-cell receptor sequencing (TCR-seq) and RNA sequencing (RNA-seq). An ongoing clinical trial comparing pre- and postoperative stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) in BM management was then leveraged to dissect radiation-induced immune responses by TCR- and RNA-seq.Results:Patients with high-grade histopathologic TIL infiltration and enriched TCR diversity demonstrated favorable prognoses in breast and lung cancer BM. Moreover, SRS/SRT treatment enhanced TCR diversity in the BM microenvironment, along with signatures of antigen processing and presentation. Finally, integrated analysis demonstrated that IR seemed to reactivate immune microenvironmental signatures normally suppressed in BM and upregulate immune signaling pathways correlated with favorable outcomes in patients with breast cancer BM.Conclusions:High TCR diversity in BM is associated with improved prognosis and highlights therapeutically tractable targets within the immune microenvironment. Moreover, we show in a prospective clinical trial that IR enhances T-cell–mediated immune responses, upregulating antigen presentation and enhancing TCR diversity in BM. These results argue for increased therapeutic investigations of radiation-induced immunomodulatory effects in BM, potentially in association with immune checkpoint inhibition.

  • Open Access

    Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment

    by Kazutaka Fukumura, Peixin Jiang, Debra Nana. Yeboa, Akshara Singareeka Raghavendra, Maria A. Gubbiotti, Clark R. Andersen, Sherise D. Ferguson, Dzifa Yawa. Duose, Yujin Kudo, Banu Arun, et al.

    Purpose: Brain metastasis (BM) is a deadly complication of systemic malignancy that has been associated with defective cellular immunity. We sought to characterize the foundational elements and clinical relevance of BM-associated immunosuppression using integrated molecular profiling in primary patient material. Experimental Design: Retrospective patient tissue cohorts of breast (n = 153) and lung (n = 153) cancer BM were stratified by histopathologic scoring of tumor-infiltrating lymphocytes (TIL) and clinical outcome, with a large subset of breast cancer samples further analyzed by T-cell receptor sequencing (TCR-seq) and RNA sequencing (RNA-seq). An ongoing clinical trial comparing pre- and postoperative stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) in BM management was then leveraged to dissect radiation-induced immune responses by TCR- and RNA-seq. Results: Patients with high-grade histopathologic TIL infiltration and enriched TCR diversity demonstrated favorable prognoses in breast and lung cancer BM. Moreover, SRS/SRT treatment enhanced TCR diversity in the BM microenvironment, along with signatures of antigen processing and presentation. Finally, integrated analysis demonstrated that IR seemed to reactivate immune microenvironmental signatures normally suppressed in BM and upregulate immune signaling pathways correlated with favorable outcomes in patients with breast cancer BM. Conclusions: High TCR diversity in BM is associated with improved prognosis and highlights therapeutically tractable targets within the immune microenvironment. Moreover, we show in a prospective clinical trial that IR enhances T-cell–mediated immune responses, upregulating antigen presentation and enhancing TCR diversity in BM. These results argue for increased therapeutic investigations of radiation-induced immunomodulatory effects in BM, potentially in association with immune checkpoint inhibition.


  • Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases

    by Lin Zhang, Jun Yao, Yongkun Wei, Zhifen Zhou, Ping Li, Jingkun Qu, Akosua Badu-Nkansah, Xiangliang Yuan, Yu-Wen Huang, Kazutaka Fukumura, et al.

    The functions of immune cells in brain metastases are unclear because the brain has traditionally been considered “immune privileged.” However, we found that a subgroup of immunosuppressive neutrophils is recruited into the brain, enabling brain metastasis development. In brain metastatic cells, enhancer of zeste homolog 2 (EZH2) is highly expressed and phosphorylated at tyrosine-696 (pY696)–EZH2 by nuclear-localized Src tyrosine kinase. Phosphorylation of EZH2 at Y696 changes its binding preference from histone H3 to RNA polymerase II, which consequently switches EZH2’s function from a methyltransferase to a transcription factor that increases c-JUN expression. c-Jun up-regulates protumorigenic inflammatory cytokines, including granulocyte colony-stimulating factor (G-CSF), which recruits Arg1+- and PD-L1+ immunosuppressive neutrophils into the brain to drive metastasis outgrowth. G-CSF–blocking antibodies or immune checkpoint blockade therapies combined with Src inhibitors impeded brain metastasis in multiple mouse models. These findings indicate that pY696-EZH2 can function as a methyltransferase-independent transcription factor to facilitate the brain infiltration of immunosuppressive neutrophils, which could be clinically targeted for brain metastasis treatment.